Sage Journals: Discover world-class research

Abstract

Background

Since dysregulation of total Interleukin (IL)-18 and IL-18 binding protein (IL-18BP) may participate in systemic lupus erythematosus (SLE) and contribute to the occurrence of non-autoimmune epilepsy, the aim of the current work is to investigate whether the interaction between IL-18 and IL-18BP plays any role in neuropsychiatric systemic lupus erythematosus related seizures.

Methods

Data from 137 SLE patients and 30 healthy controls (HC) were consecutively collected from 2020 to 2021. Serum levels of total IL-18 and IL-18BP for all patients and HC were measured by ELISA test. Free IL-18 was calculated based on the law of mass action.

Results

Among the 137 SLE patients, 103 had active disease and were classified into NPSLE (n = 50) and Non-NPSLE (n = 53) groups. Among the NPSLE patients, 16 had seizure disorders. Serum free IL-18 levels were increased in NPSLE (277.6 [150.9–428.8]pg/mL) and were correlated with disease activity (r = 0.268, p = 0.002). Moreover, serum free IL-18 levels in NPSLE patients with seizure disorders (350.9 [237.9–455.9]pg/mL) were significantly higher than the levels in those with other neuropsychiatric symptoms (237.7 [124.6–428.8] pg/mL).

Conclusions

The expression of free IL-18 was increased in neuropsychiatric systemic lupus erythematosus(NPSLE), especially in NPSLE related seizures. Also, serum levels of free IL-18 were significantly increased in active SLE patients. In this regard, free IL-18 may be involved in the pathogenesis of NPSLE related seizures and associated with disease activity.

Keywords

Interleukin-18 (IL-18)IL-18 binding protein (IL-18BP)free IL-18 neuropsychiatric systemic lupus erythematosus (NPSLE)seizure

Get full access to this article

View all access options for this article.

References

Fanouriakis

Tziolos

Bertsias

, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80: 14–25.

Schwartz

Stock

Putterman

. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019; 15: 137–152.

Carrión-Barberà

Salman-Monte

Vílchez-Oya

, et al. Neuropsychiatric involvement in systemic lupus erythematosus: a review. Autoimmun Rev 2021; 20: 102780.

Andrade

Alarcon

Gonzalez

, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008; 67: 829–834.

Kaplanski

. Interleukin-18: biological properties and role in disease pathogenesis. Immunological Rev 2018; 281: 138–153.

Esfandiari

McInnes

Lindop

, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunology (Baltimore, Md. 1950) 2001; 167(9): 5338–5347.

Bossu

Neumann

Del Giudice

, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci 2003; 100: 14181–14186.

Italiani

Manca

Angelotti

, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 2018; 20: 27.

Mende

Vincent

Kandane-Rathnayake

, et al. Analysis of serum interleukin (il)-1β and il-18 in systemic lupus erythematosus. Front Immunol 2018; 9: 1250.

10.

Wong

, et al. Elevation of plasma interleukin‐18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000; 39: 1078–1081.

11.

Umare

Pradhan

Nath

, et al. Impact of functional IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients. Lupus 2019; 28: 545–554.

12.

Mochol

Taubøll

Aukrust

, et al. Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation. Seizure 2020; 80: 221–225.

13.

Yue

Wei

, et al. Decreased expression of Rev-Erbα in the epileptic foci of temporal lobe epilepsy and activation of Rev-Erbα have anti-inflammatory and neuroprotective effects in the pilocarpine model. J Neuroinflammation 2020; 17: 43.

14.

Ryu

Kim

J-E

Kim

M-J

, et al. The protective effects of interleukin-18 and interferon-γ on neuronal damages in the rat hippocampus following status epilepticus. Neuroscience 2010; 170: 711–721.

15.

Liu

Guo

, et al. Ibuprofen exerts antiepileptic and neuroprotective effects in the rat model of Pentylenetetrazol-induced epilepsy via the COX-2/NLRP3/IL-18 pathway. Neurochem Res 2020; 45: 2516–2526.

16.

Novick

Elbirt

Miller

, et al. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2010; 34: 121–126.

17.

Hochberg

. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

18.

Gladman

Ibañez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. The J Rheumatology 2002; 29: 288–291.

19.

Franklyn

Lau

Navarra

, et al. Definition and initial validation of a lupus low disease activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.

20.

Hanly

. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004; 13: 861–864.

21.

Fisher

Cross

French

, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ilae commission for classification and terminology. Epilepsia 2017; 58: 522–530.

22.

Tso

Huang

, et al. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology 2006; 45: 1148–1153.

23.

Barclay

Shinohara

. Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathol 2017; 27: 213–219.

24.

Mortezaee

Khanlarkhani

Beyer

, et al. Inflammasome: its role in traumatic brain and spinal cord injury. J Cell Physiol 2018; 233: 5160–5169.

25.

Feng

Y-S

Tan

Z-X

L-Y

, et al. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev 2020; 64: 101192.

26.

Zhang

Jia

, et al. High-mobility group box 1 inhibition alleviates lupus-like disease in BXSB mice. Scand J Immunol 2014; 79: 333–337.

27.

Huang

Shen

, et al. Expression of HMGB1 and TLR4 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders. Ann Translational Med 2020; 8: 9.

28.

González-Duarte

Cantú-Brito

Ruano-Calderón

, et al. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008; 59: 320–323.

29.

Hanly

Urowitz

, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheumatic Dis 2012; 71: 1502–1509.

30.

Migliorini

Anzilotti

Pratesi

, et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Network 2010; 21: 264–271.

31.

Dinarello

Novick

Kim

, et al. Interleukin-18 and IL-18 binding protein. Front Immunol 2013; 4: 289.

32.

Park

Lee

Park

. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 2004; 23: 225–229.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB

Elevated serum free IL-18 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders